IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.195
EU - Europa 3.724
NA - Nord America 3.639
SA - Sud America 626
AF - Africa 286
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 12.476
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.476
SG - Singapore 1.924
IE - Irlanda 1.236
HK - Hong Kong 981
BR - Brasile 490
RU - Federazione Russa 474
CN - Cina 459
IT - Italia 403
SE - Svezia 365
DE - Germania 355
VN - Vietnam 273
UA - Ucraina 208
BJ - Benin 206
FR - Francia 147
GB - Regno Unito 139
KR - Corea 138
IN - India 114
CA - Canada 96
FI - Finlandia 93
AT - Austria 88
PL - Polonia 54
AR - Argentina 51
BD - Bangladesh 49
MX - Messico 45
JP - Giappone 44
ID - Indonesia 42
ES - Italia 38
NL - Olanda 35
ZA - Sudafrica 34
IR - Iran 30
LT - Lituania 26
TR - Turchia 26
IQ - Iraq 21
CO - Colombia 18
MA - Marocco 16
EC - Ecuador 15
CZ - Repubblica Ceca 14
VE - Venezuela 14
BE - Belgio 13
CH - Svizzera 13
PK - Pakistan 12
PY - Paraguay 12
CL - Cile 11
UZ - Uzbekistan 11
SA - Arabia Saudita 8
UY - Uruguay 7
EG - Egitto 6
IL - Israele 6
JO - Giordania 6
PH - Filippine 6
AE - Emirati Arabi Uniti 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
AZ - Azerbaigian 4
BG - Bulgaria 4
BO - Bolivia 4
JM - Giamaica 4
KE - Kenya 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TT - Trinidad e Tobago 4
BH - Bahrain 3
ET - Etiopia 3
EU - Europa 3
KZ - Kazakistan 3
LB - Libano 3
LV - Lettonia 3
MY - Malesia 3
PS - Palestinian Territory 3
PT - Portogallo 3
TN - Tunisia 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
BN - Brunei Darussalam 2
GT - Guatemala 2
HN - Honduras 2
KH - Cambogia 2
LI - Liechtenstein 2
RS - Serbia 2
SN - Senegal 2
SY - Repubblica araba siriana 2
AI - Anguilla 1
AU - Australia 1
BB - Barbados 1
BY - Bielorussia 1
CD - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DM - Dominica 1
GE - Georgia 1
GR - Grecia 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MD - Moldavia 1
ML - Mali 1
MT - Malta 1
MU - Mauritius 1
Totale 12.468
Salva come PNG Salva come JPEG
Città #
Dublin 1.234
Hong Kong 976
Singapore 687
Ashburn 401
Beijing 253
Los Angeles 219
Cotonou 206
Lawrence 149
Moscow 149
Princeton 149
Jacksonville 141
Wilmington 139
Seoul 137
Buffalo 130
San Mateo 125
Chandler 113
New York 93
Ho Chi Minh City 91
Novara 66
Dallas 63
Hanoi 63
São Paulo 60
Nuremberg 58
Dearborn 55
Helsinki 54
Brooklyn 50
Santa Clara 49
Redondo Beach 48
Vienna 47
Piemonte 46
Munich 41
Warsaw 41
Ann Arbor 38
Chennai 38
Assago 36
Denver 36
Frankfurt am Main 36
Tokyo 36
Stockholm 33
Falkenstein 32
Toronto 32
Chicago 31
Orem 31
London 30
Boardman 28
Houston 27
Montreal 27
Boston 26
Milan 26
Johannesburg 25
Phoenix 25
Poplar 25
Turin 24
Vercelli 24
Andover 23
Strasbourg 22
Atlanta 21
Amsterdam 20
Jakarta 20
Bremen 18
Manchester 18
Mexico City 17
Mumbai 17
Haiphong 16
Zanjan 16
Ankara 15
Norwalk 14
Roubaix 14
Tianjin 14
Dhaka 13
San Francisco 13
Brussels 12
Pleasantville 12
Turku 12
Da Nang 11
Woodbridge 11
Belo Horizonte 10
West Jordan 10
Brasília 9
Querétaro 9
Raleigh 9
Ribeirão Preto 9
Rio de Janeiro 9
Rome 9
Seattle 9
Tashkent 9
Bexley 8
City of London 8
Dong Ket 8
Elk Grove Village 8
Hải Dương 8
New Delhi 8
Thái Bình 8
Zurich 8
Baghdad 7
Brno 7
Calgary 7
Genoa 7
Nanjing 7
Ninh Bình 7
Totale 7.346
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 159
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 136
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 116
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 110
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 108
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 102
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 102
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 98
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 96
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 96
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 93
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 92
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 92
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 89
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 89
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 86
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 84
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 81
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 79
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 78
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 77
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 77
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 75
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 75
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 74
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 72
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 72
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 72
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 69
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 66
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 66
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 63
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 63
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 62
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 62
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 61
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 61
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 61
Antibiotic therapy and outcome from immune-checkpoint inhibitors 61
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 61
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 60
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 60
Back from the brink: EGFR inhibition in gastroesophageal cancer 60
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 60
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 59
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 58
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 58
Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis 58
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 58
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 58
Acceleration of interstitial lung disease induced by raltitrexed 57
The albumin-bilirubin grade uncovers the prognostic relationship between hepatic reserve and immune dysfunction in HIV-associated hepatocellular carcinoma 57
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 56
INTERLEUKIN-6 POLYMORPHISMS AND GENDER: RELATIONSHIP WITH THE OCCURRENCE OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH END-STAGE LIVER DISEASE 56
The Kings Score refines prognostic prediction in hepatocellular carcinoma: a novel application 56
Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy 56
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 56
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 55
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 54
GENDER-RELATED DISTRIBUTION OF THE INTERLEUKIN-1BETA AND INTERLEUKIN-1 RECEPTOR ANTAGONIST GENE POLYMORPHISMS IN PATIENTS WITH END-STAGE LIVER DISEASE 54
Assessing the impact of COVID-19 on liver cancer management (CERO-19) 54
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 54
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 54
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 54
The expression of Axl receptor tyrosine kinase influences the tumour phenotype and clinical outcome of patients with malignant pleural mesothelioma 53
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 53
Alterations of choline phospholipid metabolism in endometrial cancer are caused by choline kinase alpha overexpression and a hyperactivated deacylation pathway 53
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 53
Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy 53
Programmed cell death ligands expression drives immune tolerogenesis across the diverse subtypes of neuroendocrine tumours 52
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 51
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 51
Reliability and reproducibility of the edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens 51
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 51
International Liver Cancer Association (ILCA) White Paper on Biomarker Development for Hepatocellular Carcinoma 51
Immunotherapies for hepatocellular carcinoma 50
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 50
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 50
Isogeneic comparison of primary and metastatic lung cancer identifies CX3CR1 as a molecular determinant of site-specific metastatic diffusion 50
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 50
Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer 50
Biliary tract cancers: Molecular heterogeneity and new treatment options 50
Antibiotic Treatment and Immune Checkpoint Inhibitor Therapy in Patients with Cancer - Reply 50
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 49
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma 49
Novel immunotherapy combinations in clinical trials for hepatocellular carcinoma: will they shape the future treatment landscape? 49
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 49
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 49
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 48
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) Consortium 48
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 48
Preliminary qualification of a novel, hypoxic-based radiologic signature for trans-arterial chemoembolization in hepatocellular carcinoma 48
Prediction of Survival Among Patients Receiving Transarterial Chemoembolization for Hepatocellular Carcinoma: A Response-Based Approach 48
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 47
PETAL protocol: A phase Ib study of pembrolizumab after transarterial chemoembolization in hepatocellular carcinoma 47
Tissue biomarkers of prognostic significance in hepatocellular carcinoma. 47
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 47
Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept 46
Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy 46
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 46
Totale 6.481
Salva come PNG Salva come JPEG
Categoria #
all - tutte 91.528
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 91.528
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021318 0 0 0 0 0 5 28 5 26 113 128 13
2021/2022799 27 2 174 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/20264.437 548 499 678 1.060 1.303 349 0 0 0 0 0 0
Totale 12.845